{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:00:40Z","timestamp":1793721640446,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015229","name":"National Cancer Plan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009245","name":"Utbildningsdepartementet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["ECO20170637540"],"award-info":[{"award-number":["ECO20170637540"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["FDM202206015442"],"award-info":[{"award-number":["FDM202206015442"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015760","name":"Inserm Transfert SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012958","name":"Morocco Ministry of Higher Education Scientific Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006431","name":"Canc\u00e9rop\u00f4le \u00cele-de-France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","award":["PLBIO24-107"],"award-info":[{"award-number":["PLBIO24-107"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","award":["PEDIAHR22-009"],"award-info":[{"award-number":["PEDIAHR22-009"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jhep.2025.11.023","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T15:56:53Z","timestamp":1764431813000},"page":"906-919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting ATR to overcome cisplatin resistance in hepatoblastoma"],"prefix":"10.1016","volume":"84","author":[{"given":"Pierre","family":"Morel-Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Cornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-801X","authenticated-orcid":false,"given":"Jill","family":"Pilet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Asif-Laidin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphn\u00e9e","family":"Bourdeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Cavaignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9o Z.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Pire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Imbeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Morcrette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblle","family":"Cadiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6671-0940","authenticated-orcid":false,"given":"Solenne","family":"Marmier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeineb","family":"Elamouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-5650","authenticated-orcid":false,"given":"Christophe","family":"Chardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Sarnacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Taque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0791-5505","authenticated-orcid":false,"given":"Catherine","family":"Guettier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ferlicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Branchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Fresneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-3939","authenticated-orcid":false,"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Desdouets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Nault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-0334","authenticated-orcid":false,"given":"Jessica","family":"Zucman-Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-2271","authenticated-orcid":false,"given":"Sandra","family":"Rebouissou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.11.023_bib1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/sj.bjc.6604335","article-title":"Perinatal risk factors for hepatoblastoma","volume":"98","author":"Spector","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.11.023_bib2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mpo.10177","article-title":"Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin","volume":"39","author":"Prokurat","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jhep.2025.11.023_bib3","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2022.04.035","article-title":"Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults","volume":"77","author":"Sumazin","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.11.023_bib4","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0022-3476(05)80297-5","article-title":"Risk of hepatoblastoma in familial adenomatous polyposis","volume":"119","author":"Giardiello","year":"1991","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2025.11.023_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrendo.2017.166","article-title":"Expert consensus document: clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement","volume":"14","author":"Brioude","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jhep.2025.11.023_bib6","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.1038\/s41467-023-42418-9","article-title":"Preneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma","volume":"14","author":"Pilet","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.11.023_bib7","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/2159-8290.CD-20-1809","article-title":"Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer","volume":"11","author":"Hirsch","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2025.11.023_bib8","first-page":"5041","article-title":"Loss of maternal alleles on chromosome arm 11p in hepatoblastoma","volume":"54","author":"Albrecht","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2025.11.023_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hep.29672","article-title":"New insights into diagnosis and therapeutic options for proliferative hepatoblastoma","volume":"68","author":"Hooks","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.11.023_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","article-title":"Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer","volume":"14","author":"Cairo","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2025.11.023_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jhep.2020.03.025","article-title":"Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications","volume":"73","author":"Carrillo-Reixach","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.11.023_bib12","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1038\/s41467-021-25430-9","article-title":"Genetic and epigenetic basis of hepatoblastoma diversity","volume":"12","author":"Nagae","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.11.023_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.28888","article-title":"Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups","volume":"65","author":"Sumazin","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.11.023_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","article-title":"Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration","volume":"18","author":"Meyers","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.11.023_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113583","article-title":"Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival","volume":"200","author":"Pire","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.11.023_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1158\/1535-7163.MCT-22-0335","article-title":"Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma","volume":"22","author":"Abril-Fornaguera","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2025.11.023_bib17","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1038\/s41467-024-47280-x","article-title":"Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma","volume":"15","author":"Roehrig","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.11.023_bib18","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","article-title":"Hep G2 is a hepatoblastoma-derived cell line","volume":"40","author":"L\u00f3pez-Terrada","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2025.11.023_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102446","article-title":"The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution","volume":"69","author":"O\u2019Neill","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2025.11.023_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2025.11.023_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2025.11.023_bib22","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2025.11.023_bib23","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1038\/s41467-023-39717-6","article-title":"Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma","volume":"14","author":"Fang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.11.023_bib24","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.18632\/oncotarget.27237","article-title":"Volasertib preclinical activity in high-risk hepatoblastoma","volume":"10","author":"Kats","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2025.11.023_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/HEP.0000000000000601","article-title":"Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response","volume":"80","author":"Failli","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.11.023_bib26","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-08-2878","article-title":"Activation of phosphatidylinositol-3\u2019-kinase\/AKT signaling is essential in hepatoblastoma survival","volume":"15","author":"Hartmann","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.11.023_bib27","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cmet.2019.01.002","article-title":"Inhibiting glutamine-dependent mTORC1 activation ameliorates liver cancers driven by \u03b2-catenin mutations","volume":"29","author":"Adebayo Michael","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2025.11.023_bib28","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.ejca.2011.12.032","article-title":"Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients","volume":"48","author":"Wagner","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.11.023_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22140","article-title":"Everolimus inhibits hepatoblastoma by inducing autophagy-dependent ferroptosis","volume":"85","author":"Huang","year":"2024","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.jhep.2025.11.023_bib30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.18632\/oncotarget.26668","article-title":"mTOR inhibition affects Yap1-\u03b2-catenin-induced hepatoblastoma growth and development","volume":"10","author":"Molina","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2025.11.023_bib31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1399-3046.2011.01515.x","article-title":"The use of everolimus in pediatric liver transplant recipients: first experience in a single center","volume":"15","author":"Nielsen","year":"2011","journal-title":"Pediatr Transpl"},{"key":"10.1016\/j.jhep.2025.11.023_bib32","first-page":"367","article-title":"Experience with the mTOR inhibitor everolimus in pediatric liver graft recipients","volume":"10","author":"Wehming","year":"2023","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jhep.2025.11.023_bib33","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/15384047.2016.1235664","article-title":"Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma","volume":"17","author":"Beck","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jhep.2025.11.023_bib34","series-title":"Multi-dimensional profiling of hepatoblastomas and patient-derived tumor organoids uncovers tumor subpopulations with divergent WNT activation profiles and identifies pan-hepatoblastoma drug sensitivities","author":"Kluiver","year":"2023"},{"key":"10.1016\/j.jhep.2025.11.023_bib35","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2024.01.003","article-title":"A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma","volume":"80","author":"Espinoza","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.11.023_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13046-024-03221-6","article-title":"Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma","volume":"43","author":"Demir","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.11.023_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as Cancer Therapy: a new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.11.023_bib38","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2025.11.023_bib39","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2025.11.023_bib40","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4161\/cc.9.3.10556","article-title":"Mechanism of p53 stabilization by ATM after DNA damage","volume":"9","author":"Cheng","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jhep.2025.11.023_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12943-024-01933-z","article-title":"The DNA damage sensor ATM kinase interacts with the p53 mRNA and guides the DNA damage response pathway","volume":"23","author":"Karakostis","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhep.2025.11.023_bib42","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-22-0685","article-title":"Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors","volume":"22","author":"Turchick","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2025.11.023_bib43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jhep.2025.11.023_bib44","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhep.2025.11.023_bib45","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/0008-5472.CAN-11-2904","article-title":"ATR-ATRIP kinase complex triggers activation of the Fanconi anemia DNA repair pathway","volume":"72","author":"Shigechi","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2025.11.023_bib46","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2018\/e478s","article-title":"DNA repair pathways and cisplatin resistance: an intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.jhep.2025.11.023_bib47","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.11.023_bib48","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.11.023_bib49","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1535-7163.MCT-23-0094","article-title":"Elimusertib has antitumor activity in preclinical patient-derived pediatric solid tumor models","volume":"23","author":"Pusch","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2025.11.023_bib50","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.4161\/cc.7.18.6689","article-title":"Activation of ATR and related PIKKs","volume":"7","author":"Mordes","year":"2008","journal-title":"Cell Cycle"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825027059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825027059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:56:10Z","timestamp":1777528570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825027059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0168827825027059"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.11.023","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ATR to overcome cisplatin resistance in hepatoblastoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}